RASopathies. Part I: Genetics and therapeutic considerations

Area of Science:

• Genetics
• Cell Biology
• Developmental Biology

Background:

• RASopathies are developmental disorders stemming from genetic variants in RAS and related proteins.
• These variants disrupt the critical RAS signaling pathway governing cell growth and development.
• The RAS pathway's role in cell proliferation links RASopathies to both developmental abnormalities and cancer predisposition.

Purpose of the Study:

• To review the genetic and biochemical basis of RASopathies.
• To categorize RASopathies into germline and mosaic patterns.
• To explore the intersection of RASopathies, cancer, and potential therapeutic interventions.

Main Methods:

• Classification of RASopathies based on genetic patterns (germline vs. mosaic).
• Review of associated syndromes within each category.
• Analysis of the RAS pathway's role in oncogenesis and therapeutic implications.

Main Results:

• Germline RASopathies include Noonan syndrome and Costello syndrome, among others.
• Mosaic RASopathies encompass conditions like McCune-Albright syndrome and epidermal nevus syndrome.
• The RAS pathway's dysregulation in RASopathies increases cancer risk, while some cancer therapies may benefit these patients.

Conclusions:

• Understanding RAS pathway genetics is crucial for diagnosing and potentially treating RASopathies.
• Targeting the RAS pathway presents therapeutic opportunities for both RASopathies and cancers.
• Further research into RAS biochemistry may reveal novel pharmacological strategies.